Daniele Piomelli, PhD. - Another approach was discussed by D. Piomelli (University of California, Irvine). URB 597, an inhibitor of fatty acid amide hydrolase (FAAH), is expected to increase anandamide signaling and is being currently clinically tested in the therapy of pain. An increase in
anandamide signaling may also be useful in the therapy of depression. This is a novel approach to the development of antidepressants. The signaling can be enhanced by blocking anadamide metabolism or by inhibiting anandamide reuptake. Piomelli considers blockade of fatty acid amide hydrolase (FAAH) a promising approach. It is conceivable that drugs acting by this mechanism will be effective in patients resistant to the currently available antidepressants.